secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001193125-23-200535
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q2 net sales $81.3M (+21.5% YoY); raises FY2023 growth guidance to mid-to-high teens
--------------------------------------------------------------------------------

- Net sales $81.3M (+21.5% YoY); net income $1.2M; Adj. EBITDA $14.1M (17.4% of sales).
- Raises full-year 2023 net sales growth guidance to mid-to-high teens.
- Appoints Doug Rice as CFO, rounding out executive team.
- Reports favorable appellate ruling affirming dismissal of securities class action.
- Announced strategic realignment focusing on Wound & Surgical businesses to improve profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000119312523200535/0001193125-23-200535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000119312523200535/d472149d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-200535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer